DVT/PE Flashcards
1
Q
Post thrombotic syndrome
A
C/F
- Chronic swelling - Chronic pain - Chronic discomfort when walking - Chronic skin discoloration - Pron for infection/ulceration
Treatment:
18 months of high pressure compression stocking
2
Q
overview of anticoagulant management in DVT/PE
A
- CKD with CrCl < 25
warfarin with need of bridging clexane for 1st 5 days - CKD CrCl > 25 /Cancer / pregnancy
clexane 1mg/kg BD or 1.5mg/Kg daily - CKD CrCl > 25/others others –> NOAC
3
Q
NOAC and doses
A
- Apixaban (Eliquis) best (CrCl should be > 25)
Treatment dose: 10mg PO BD for 7 days
Maintainance dose: 5mg PO BD - Rivaroxiban (Xarelto) (CrCl should be > 30)
Treatment dose: 15mg PO BD for 7 days
Maintainance dose: 20mg PO daily - Dabigatran (Pradaxa)
a. clexane D1-5 therapeutic dose then
b. Dabigatran on D6 forward
- < 75 years and CrCl > 50 –> 150mg PO BD
- > 75 years OR CrCl 30-50 –> 110mg PO BD
the only has antidot is Dabigatran (Pradaxa)
4
Q
distal DVT
A
C/F
- swelling : increase circumference of calf area - Redness - Tenderness - Homan’s sign +ve : increase pain on dorsiflexion - Dilated superficial veins
Investigation
- Doppler ultrasound of deep veins of the affected leg
Treatment: anticoagulation
Other management
- Monitor for signs of Pulmonary embolism - Early mobilisation - Monitor for signs of Pulmonary embolism - Prevent post thrombotic syndrome
5
Q
Duration of treatment
A
- unprovoked (no cause identified) –> 3/12
- provoked and cause removed
a. distal DVT –> 6/52
b. Proximal DVT/PE –> 3/12
OR (same as above)
- proximal DVT/PE –> 3/12
- Distal DVT
a. provoked but cause removed –> 6/52
b. unprovoked –> 3/12
6
Q
risk of recurrent DVTs (7)
A
- previous DVT
- pregnancy
- Cancer
- unprovoked DVT
- provoked proximal DVT/PE
- thrombophilias
- antiphospholipid syndrome
7
Q
Thrombophilia screen (7)
A
Causes
- Factor V leiden deficiency - Prothrombin gene mutation - Anti-thrombin III deficiency - Protein C deficiency - Protein S deficiency - Antiphospholipid syndrome esp in SLE - Homocysteine level (high)
Investigation
- Factor V Leiden - Prothrombin - Anti-thrombin III level - Protein C - Protein S - Antiphospholipid Ab - Homocystin level
8
Q
Superficial thrombophlebitis
A
- due to IV cannula –> NSAIDs
2. in veins of thigh: clexane (prevention) 40mg SC for 6/12
9
Q
assessment of Pulmonary embolism
A
- Wells score > 4 –> CTPA
- wells score < 4 –> PERC score
a. PERC score –> all no–> no PE
b. PERC score –> x1 yes
- D-dimer -ve –> no PE
- D-dimer +ve –> CTPA
10
Q
risk of intracranial bleeding while on anticoagulant
A
HAS-BLED
- HTN > 160 (1)
- abnormal liver/kidney function (1)
- history of stroke (1)
- bleeding tendency (1)
- labile INR (1)
- Elderly > 65 (1)
- Drug (antiplatelet, NSAIDs) (1)
total score of 3 or more –> increase risk of bleeding